Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 15Neoplasm Metastasis 7Lung Neoplasms 5Neoplasms 3Adenocarcinoma 3Recurrence 2Lymphoma, Large-Cell, Anaplastic 2Granuloma, Plasma Cell 2Colorectal Neoplasms 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Relapsed Pediatric Solid Tumor 1Rare Tumor 1Neurofibromatosis 2 1Lymphoma, Follicular 1Lung Adenocarcinoma Metastatic 1Glioma 1Glioblastoma 1Gallbladder Neoplasms 1Endometrial Cancer Recurrent 1Diffuse Intrinsic Pontine Glioma 1Castration-resistant Prostate Cancer 1Carcinoma, Squamous Cell 1Carcinoma, Lobular 1Breast Neoplasms 1Advanced Cancers 1

Interventions

Cyclophosphamide 115Dexamethasone 70fludarabine phosphate 57Cytarabine 56fludarabine 52Rituximab 51Peripheral Blood Stem Cell Transplantation 40Etoposide 40Gemcitabine 39Lenalidomide 38pembrolizumab 33Radiotherapy 33Busulfan 33Filgrastim 32Carboplatin 31Methotrexate 30Cyclosporine 29Cisplatin 29Bortezomib 29Mycophenolic Acid 28Melphalan 28venetoclax 27Paclitaxel 26Whole-Body Irradiation 24Antilymphocyte Serum 23Temozolomide 22Granulocyte Colony-Stimulating Factor 20Calcium Dobesilate 20Bevacizumab 20Tacrolimus 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Recurrence × Crizotinib × Clear all
NCT04292119 2021-03-10

Lorlatinib Combinations in Lung Cancer

Massachusetts General Hospital

Phase 1/2 Unknown
96 enrolled
Thoracic

Lung Neoplasms, Recurrence

NCT01531361 2021-01-22

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

M.D. Anderson Cancer Center

Phase 1 Completed
46 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡